Search - tctmd.com

Displaying 981 - 1000 of 1522

Sort: Relevancy | Date

Presentation Fellows 2015

Case 2

Presenter: Roxana Mehran, David J. Cohen, Kevin J. Croce

May 15, 2015

Presentation Fellows 2015

Case 1

Presenter: Roxana Mehran, David J. Cohen, Robert W. Yeh

May 15, 2015

Presentation Fellows 2015

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Manish A. Parikh, Roxana Mehran

May 15, 2015

Presentation Fellows 2015

Antithrombin Pharmacology for the Interventionalist

Presenter: Manish A. Parikh, Roxana Mehran, David J. Cohen

May 15, 2015

Presentation Fellows 2015

Antiplatelet Therapy for the Interventionalist

Presenter: Manish A. Parikh, Roxana Mehran, Gregg W. Stone

May 15, 2015

Presentation

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Presenter: Usman Baber

May 11, 2015

Presentation

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Presenter: Roxana Mehran

May 08, 2015

Presentation

Activated Clotting Time (ACT) and Outcomes During PCI for NSTEMI: Insights from FUTURA OASIS-8

Presenter: Gregory Ducrocq

April 24, 2015

Presentation

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Presenter: K.A. Fiedler

April 22, 2015

Presentation

Association of DAPT With Reduced Major Adverse Cardiovascular Events in Symptomatic PAD

Presenter: E.J. Armstrong

April 22, 2015

Presentation

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

Presenter: Gregg W. Stone

April 14, 2015

Presentation ARCH 2015

Acute Coronary Syndromes

Presenter: Richard G. Bach

April 10, 2015

Presentation

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

Presenter: D. J. Kereiakes

March 24, 2015

Presentation

BRIGHT: Bivalirudin vs Heparin With or Without Tirofiban During Primary PCI in Acute MI

Presenter: Yaling Han

March 23, 2015

Presentation

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Presenter: T. Palmerini

March 18, 2015

Presentation ACC 2015

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Presenter: Marc S. Sabatine

March 14, 2015

Presentation

Atheroma Progression in Hyporesponders to Statin Therapy

Presenter: Y. Kataoka

March 11, 2015

Presentation

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Presenter: Martine Gilard

March 10, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Presentation CADECI 2015

Importancia De La Terapia Combinada Bajo Las Nuevas Guías Para El Manejo De La Hipertensión Arterial

Presenter: Dr. Enrique G?mez ?lvarez

February 20, 2015

Advertisement

Case 2

Case 1

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Antithrombin Pharmacology for the Interventionalist

Antiplatelet Therapy for the Interventionalist

PROMETHEUS: Clinical Assessment of ACS Patients Managed With PCI and Treated With Prasugrel or Clopidogrel

Ticagrelor vs Clopidogrel in Troponin-Negative ACS Patients Undergoing Ad Hoc PCI

Activated Clotting Time (ACT) and Outcomes During PCI for NSTEMI: Insights from FUTURA OASIS-8

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Association of DAPT With Reduced Major Adverse Cardiovascular Events in Symptomatic PAD

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

Acute Coronary Syndromes

Antiplatelet Therapy Duration Following BMS or DES: The DAPT Randomized Clinical Trial

BRIGHT: Bivalirudin vs Heparin With or Without Tirofiban During Primary PCI in Acute MI

Mortality in Pts Treated With Extended Duration Dual Antiplatelet Therapy (DAPT) After DES

Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Atheroma Progression in Hyporesponders to Statin Therapy

ITALIC: 6- vs 24-Month DAPT After Implantation of DES in Patients Nonresistant to Aspirin

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Importancia De La Terapia Combinada Bajo Las Nuevas Guías Para El Manejo De La Hipertensión Arterial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content